**Supplemental Digital Content 1. Patient Demographics and Clinical Characteristics at Baseline**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Placebo****(n=7)** | **IV Golimumab 2 mg/kg****(n=5)** | **Total****(n=12)** |
| Age, years, mean (SD), median (IQR) | 48.1 (5.8), 49.0 (44.0‑53.0) | 42.6 (12.4), 40.0 (39.0‑44.0) | 45.8 (9.1), 44.5 (39.5‑52.0) |
| Male, n (%) | 7 (100) | 5 (100) | 12 (100) |
| Body mass index, kg/m2, mean (SD) | 26.4 (9.2) | 24.3 (6.1) | 25.5 (7.8) |
| Race, white, n (%) | 7 (100) | 5 (100) | 12 (100) |
| Time since diagnosis of AS, years, mean (SD), median (IQR) | 7.3 (6.1), 8.6(0.8‑14.3) | 10.8 (10.1), 10.2 (1.3‑21.0) | 8.7 (7.8), 9.0 (1.0‑14.6) |
| Time since inflammatory back pain first occurred, years, mean (SD), median (IQR) | 17.9 (11.6), 16.0 (9.0‑27.0) | 16.6 (12.4), 12.0 (9.0‑23.0) | 17.3 (11.4), 15.0 (9.0‑25.0) |
| Time since symptoms of spondyloarthritis first occurred, years, mean (SD), median (IQR) | 7.9 (6.2), 7.0(1.0‑14.0) | 12.0 (9.4), 11.0 (4.0‑20.0) | 9.6 (7.6), 9.0 (3.0‑14.0) |
| HLA-B27 positive, n (%) | 7 (100) | 5 (100) | 12 (100) |
| CRP, mg/L, mean (SD), median, (IQR) | 40.4 (22.0), 33.9 (24.2‑64.3) | 15.0 (9.5), 19.0 (8.6‑21.6) | 29.8 (21.6), 24.2 (14.2‑43.9) |
| ASDAS, mean (SD) | 4.8 (0.7) | 4.1 (1.3) | 4.5 (1.0) |
| BASDAI (0–10), mean (SD) | 7.2 (1.2) | 7.2 (2.3) | 7.2 (1.6) |
| ASAS |  |  |  |
| BASFI (0–10), mean (SD) | 6.7 (0.5) | 7.5 (1.6) | 7.0 (1.1) |
| Patient’s global assessment of disease activity (VAS 0–10), mean (SD) | 7.9 (1.2) | 7.9 (1.2) | 7.9 (1.1) |
| Patient’s assessment of total back pain (VAS 0–10), mean (SD) | 8.0 (0.6) | 7.2 (1.4) | 7.7 (1.0) |
| Inflammation (from BASDAIa), mean (SD) | 7.2 (1.5) | 7.6 (2.2) | 7.4 (1.7) |
| BASMI (0–10), mean (SD) | 5.4 (0.7) | 6.2 (1.0) | 5.7 (0.9) |
| UCSF enthesitis index (0–17), mean (SD) | 6.1 (5.1) | 4.8 (3.5) | 5.6 (4.3) |
| ASQoL (0–18), mean (SD) | 12.3 (2.2) | 14.2 (1.9) | 13.1 (2.2) |
| Night back pain (VAS 0–10 cm), mean (SD) | 7.3 (1.8) | 8.0 (0.7) | 7.6 (1.4) |
| AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society Criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C‑reactive protein; HLA-B27, human leukocyte antigen B27; IQR, interquartile range; IV, intravenous; SD, standard deviation; UCSF, University of California San Francisco; VAS, visual analog scaleaAverage of 2 BASDAI questions concerning morning stiffness |